Skip to main content

Metastatic Castration Resistant Prostate Cancer CAAA817B12301 ActFirst

Status: Open to Enrollment
Email us to enroll

Study details

View study details on clinicaltrials.gov.

Locations

  • Santa Barbara

Clinical trial FAQs

Information for patients and study volunteers, including frequently asked questions.

A Phase III, Open-label, Multi-center, Randomized Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive Metastatic Castration Resistant Prostate Cancer

Mukul Gupta, M.D., FACP
Mukul Gupta, M.D., FACP
Principal investigator
View profile

Sub-Investigators

Eric M Bank, M.D., Maira P Campos, M.D., MPH, Ryan F Kendle, M.D., Andrea L Kremsreiter, PA-C, Gregg C Newman, M.D., Linda M Reidy, MSN, FNP-C, OCN

Email us to enroll

Related clinical trials

View all clinical trials
  • Clinical trial

    Prostate Cancer Recurrence After Prostatectomy Barrigel®

    Randomized Trial of Barrigel® to Increase Distance Between the Rectum and Prostate Bed to Decrease Rectal Dose in Patients Receiving Moderately Hypofractionated Radiation Therapy Who Have Had Recurrence of Prostate Cancer After Prostatectomy

    Status: Open to Enrollment

  • Clinical trial

    Advanced Staged Cancer Targeted Therapy ASCO TAPUR

    Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Status: Open to Enrollment

  • Clinical trial

    Adverse Effects of Chemotherapy Shengbai Solution

    A Randomized, Blinded, Placebo-controlled Trial of Shengbai Oral Formula to Assess Safety and Alleviation of Adverse Effects in Patients With Cancer Undergoing Chemotherapy

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Advance Ovarian Cancer FRAmework-01 J5E-MC-JZXB

    FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

    Status: Open to Enrollment

  • Clinical trial

    Adjuvant Advanced Pancreatic Adenocarcinoma

    Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

    Status: Open to Enrollment

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?